Vertex Pharmaceuticals Inc. (VRTX) News
Filter VRTX News Items
VRTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VRTX News Highlights
- VRTX's 30 day story count now stands at 45.
- Over the past 28 days, the trend for VRTX's stories per day has been choppy and unclear. It has oscillated between 1 and 7.
- The most mentioned tickers in articles about VRTX are AAPL, BEAT and MILE.
Latest VRTX News From Around the Web
Below are the latest news stories about Vertex Pharmaceuticals Inc that investors may wish to consider to help them evaluate VRTX as an investment opportunity.
Vertex Pharmaceuticals: Shares Up as Business ExpandsVertex Pharmaceuticals (VRTX) shares are up more than 27% over the past three months, after earnings rebounded from a 2021 second-quarter slump, created by higher research and development costs for certain collaborations.The company's fundamentals appear to be solid, as sales and earnings are growing on continued strong progress in the company's business. So, I'm bullish on this stock.Vertex Pharmaceuticals is a biotechnology developer of treatments for patients affected with cystic fibrosis (CF), an inherited disease that causes severe damage to the respiratory, digestive tract and other organs.The company markets Kaftrio in Europe and other non-U.S. countries, and Trikafta in the U.S. |
VIR Q4 Earnings Beat on Higher Revenues From Covid TreatmentVIR beat earnings estimates in the fourth quarter on higher sotrovimab revenues for COVID-19 patients. |
Why Is Vertex (VRTX) Up 0.9% Since Last Earnings Report?Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Radius (RDUS) Q4 Earnings & Revenues Surpass EstimatesRadius (RDUS) beats on earnings and sales in the fourth quarter. The guidance is disappointing. |
Aerie (AERI) Q4 Earnings Beat Estimates, Revenues Up Y/YAerie (AERI) beats earnings and sales estimates for the fourth quarter of 2021. AERI's shares increase in the after-market trading session following the news. |
Intellia (NTLA) Q4 Loss Wider Than Expected, Revenues Up Y/YIntellia Therapeutics (NTLA) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates. |
Three Shrewd Moves In A Bad Market By Top Fidelity BrainsIn a bad market, what's one of the top Fidelity funds up to? Growth Discovery, one of the best mutual funds anywhere, is making three savvy moves. |
Agios (AGIO) Loss Wider Than Expected in Q4, Revenues NilAgios Pharmaceuticals (AGIO) posts wider-than-expected loss for the fourth quarter of 2021. It does not record any revenues in the quarter. |
Theravance's (TBPH) Q4 Earnings and Sales Miss EstimatesTheravance (TBPH) reports wider-than-expected loss for the fourth quarter of 2021. Revenues decline year over year. |
Arena (ARNA) Q4 Loss Wider Than Expected, Etrasimod in FocusArena Pharmaceuticals (ARNA) misses on Q4 bottom line. Top-line data from several phase III studies on etrasimod are slated for release in 2022. |